1477524-11-0

Basic information

• Product Name: methyl 2-(4-(4-(5-(5-tert-butyl-1,3,4-oxadiazol-2-ylamino)pyridin-2-yl)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)acetate
• Synonyms: methyl 2-(4-(4-(5-(5-tert-butyl-1,3,4-oxadiazol-2-ylamino)pyridin-2-yl)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)acetate
• CAS NO: 1477524-11-0
• Molecular Weight: 476.575
• Mol File: 1477524-11-0.mol

Chemical Properties

• CAS DataBase Reference: methyl 2-(4-(4-(5-(5-tert-butyl-1,3,4-oxadiazol-2-ylamino)pyridin-2-yl)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(4-(4-(5-(5-tert-butyl-1,3,4-oxadiazol-2-ylamino)pyridin-2-yl)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)acetate(1477524-11-0)
• EPA Substance Registry System: methyl 2-(4-(4-(5-(5-tert-butyl-1,3,4-oxadiazol-2-ylamino)pyridin-2-yl)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)acetate(1477524-11-0)

Safety Data

• Hazardous Substances Data: 1477524-11-0(Hazardous Substances Data)

Upstream product

• 1477524-04-1 methyl 8-(4-bromophenyl)-1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 1477524-05-2 (8-(4-bromophenyl)-1,4-dioxaspiro[4.5]decan-8-yl)methanol 
• 1477524-06-3 4-(4-bromophenyl)-4-(hydroxymethyl)cyclohexan-1-one 
• 1477524-07-4 methyl 2-(4-(4-bromophenyl)-4-(hydroxymethyl)cyclohexylidene)acetate 
• 1477524-08-5 methyl 2-(4-(4-bromophenyl)-2-oxabicyclo[2.2.2]octan-1-yl)acetate 
• 1477524-09-6 methyl 2-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)acetate 
• 1384265-30-8 methyl 1-(4-bromophenyl)-4-oxocyclohexane-1-carboxylate 
• 42826-42-6 pivalohydrazide 
• 1477524-10-9 methyl 2-(4-(4-(5-aminopyridin-2-yl)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)acetate 
• 102368-13-8 1,1'-Thiocarbonyldi-2(1H)-pyridone 

Downstream Products

• 1477523-81-1 2-(4-(4-(5-(5-tert-butyl-1,3,4-oxadiazol-2-ylamino)pyridin-2-yl)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)acetic acid 

Relevant articles and documents

CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS

The invention relates to compounds of formula (I): useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.